This HTML5 document contains 183 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n13https://w3id.org/oc/corpus/br/
n12http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q27851579
rdf:type
wikibase:Item
schema:description
artigo científico 2010年论文 2010年論文 ২০১০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ wetenschappelijk artikel (gepubliceerd op 2010/10/01) научная статья 2010年论文 научни чланак artigo científico (publicado na 2010/10/01) vitenskapelig artikkel bilimsel makale 2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած artikull shkencor tudományos cikk 2010年论文 vitskapeleg artikkel บทความทางวิทยาศาสตร์ naučni članak artículo científico publicado en 2010 مقالهٔ علمی 2010年論文 vědecký článek publikovaný v roce 2010 2010 nî lūn-bûn videnskabelig artikel (udgivet 2010/10/01) 2010年论文 articolo scientifico (pubblicato il 2010/10/01) artigo científico (publicado na 2010) מאמר מדעי vedecký článok (publikovaný 2010/10/01) مقالة علمية (نشرت في أكتوبر 2010) 2010年論文 мақолаи илмӣ article científic سائنسی مضمون teaduslik artikkel 2010年論文 mokslinis straipsnis artykuł naukowy articol științific artikulong pang-agham научни чланак научна статия наукова стаття, опублікована в жовтні 2010 2010年论文 სამეცნიერო სტატია 2010年论文 мақолаи илмӣ wissenschaftlicher Artikel scienca artikolo bài báo khoa học article scientific artículu científicu espublizáu en 2010 2010 թվականի հոտեմբերին հրատարակված գիտական հոդված 2010年の論文 scientific article tieteellinen artikkeli 2010년 논문 επιστημονικό άρθρο 2010年論文 article scientifique (publié 2010) vetenskaplig artikel
p:P577
wds:Q27851579-12CCD6DD-AE0B-4ABF-A40D-D382B41FC052
wdt:P577
2010-10-01T00:00:00Z
p:P407
wds:Q27851579-E18A9620-F264-47E2-81C9-291953938E8C
wdt:P407
wd:Q1860
p:P2860
wds:Q27851579-A86256BD-38BC-489E-8ACB-76C60DBD1631 wds:Q27851579-C553B55F-DA22-44DC-AF4E-9BF6EB9D1390 wds:Q27851579-D3AE3121-22DB-474D-9672-B306313985C1 wds:Q27851579-D61DFB20-819B-4AC9-A403-2E0231B0411E wds:Q27851579-DA34B8A0-7CE6-459E-987E-3D836BBD8D15 wds:Q27851579-DFDD9B33-ECC9-4C6F-8543-35BAB3FC2F12 wds:Q27851579-560BD579-F163-4872-93AA-34735F0066B3 wds:Q27851579-5F1CDD51-D07E-48A4-BDC6-0475681B4D37 wds:Q27851579-6C9D077F-3E19-42EE-B825-69C020C01B1D wds:Q27851579-872AF7A4-9FD5-4D77-A9A1-CC426BF0E475 wds:Q27851579-8B2D0231-9DB0-4937-899A-9844AB165BD6 wds:Q27851579-8B3AE9D3-887A-4B3E-B3CC-56CAEDE82CC9 wds:Q27851579-9A460645-EA0B-4A5F-9CC0-D692DB4DEB75 wds:Q27851579-9FE32D11-1BE0-4DDE-8B66-5C362A0A5F46 wds:Q27851579-E3C2A956-7B92-406A-865D-46D4C590D9E2 wds:Q27851579-1550C970-616F-4915-AC25-F8822B14D063 wds:Q27851579-1718CFB0-17EB-42DD-B73E-8B9CE38AE117 wds:Q27851579-2BA59868-42CB-42AF-8011-570637CEC73F wds:Q27851579-4D5349D7-0453-4D93-B812-C6895B3C21AB wds:Q27851579-4DEF913E-6460-4DB8-AB89-630B5B9F6FFA wds:Q27851579-06D2D8CF-98C0-4B74-AE30-BBD13AD9A945
wdt:P2860
wd:Q45929224 wd:Q44298388 wd:Q34139532 wd:Q34746103 wd:Q35018629 wd:Q35594041 wd:Q40390558 wd:Q40760923 wd:Q32073544 wd:Q40559231 wd:Q45042550 wd:Q33680292 wd:Q46233590 wd:Q80794418 wd:Q45040849 wd:Q39981715 wd:Q40737646 wd:Q40543180 wd:Q40252880 wd:Q34664542 wd:Q44068434
p:P2093
wds:Q27851579-765C691A-4524-4A86-9B49-1795B5E9E21D wds:Q27851579-5A820B02-FC41-44DC-BCD3-32FCD839AFA5 wds:Q27851579-56E83D5E-2EB2-493E-BCD2-88A31AF15B50 wds:Q27851579-7CF0B3EA-5AFB-4397-8507-A1CE5DDE3013 wds:Q27851579-BAFF011C-9EB0-454D-88F1-1EF60B575325 wds:Q27851579-AECBAD2A-87CC-46B3-B976-26F3339333C5 wds:Q27851579-A3369184-E3DB-46C3-94ED-50E422D0B331 wds:Q27851579-D45E8E50-9C88-4DA9-B668-2F0822BD69F8 wds:Q27851579-D24EAF18-AFDB-457B-AF81-074FF7927275 wds:Q27851579-154A916A-EC01-49A5-94C5-BA13BD0E6CE9 wds:Q27851579-49C10518-52D5-44AF-8BAA-C52290433099 wds:Q27851579-4B67CD21-4615-44B7-A3AD-88C0ED8CB1E6 wds:Q27851579-3476008C-AA3E-43B4-952B-0D86714E48B0 wds:Q27851579-F976E826-A8CA-4BAC-9409-8BFC3884E211 wds:Q27851579-F765CC07-CDDF-46CB-B7F0-504446D4B407
p:P3181
wds:Q27851579-CFE1B309-E5FA-4ADE-81DB-EDB8A0670441
wdtn:P3181
n13:2213766
wdt:P2093
Jodi Virkus Richard M Stone Thomas Fischer Carlo Lanza Catherine Dutreix Eric J Feldman Ilene Galinsky Daniel J Deangelo Virginia M Klimek Gary J Schiller Edward Fox Stephen D Nimer Francis J Giles Alice Huntsman-Labed D Gary Gilliland
wdt:P3181
2213766
rdfs:label
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
skos:prefLabel
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
schema:name
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
p:P50
wds:Q27851579-2752AFBC-15B2-4BE3-B219-560CDB9967DB wds:Q27851579-88FFC42C-525C-4883-9604-8C1F89BDC675
wdt:P50
wd:Q96145785 wd:Q19283882
p:P1476
wds:Q27851579-18F5AAF9-333E-4BE6-86FF-32CF964820F9
wdt:P1476
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.
p:P304
wds:Q27851579-685BF53B-C160-40DE-90AF-507D4AD2039D
wdt:P304
4339-45
p:P31
wds:Q27851579-499DF133-FCDF-419D-8854-C69492B77DE4
wdt:P31
wd:Q13442814
p:P921
wds:Q27851579-A5CB90EA-EC64-45F9-96A9-0E4132DA03A6 wds:Q27851579-96AE62C4-7DFA-40E6-984E-11EFC79D32BC wds:Q27851579-3A6B1458-BA4D-4512-8FAA-3DFB132B1B11 wds:Q27851579-04645B1B-8093-4A3E-A118-9B6BF2B334E1
wdt:P921
wd:Q954625 wd:Q264118 wd:Q181600 wd:Q29496
p:P698
wds:Q27851579-30B0DC86-066A-4DBB-9C8A-0F526968B525
wdtn:P698
n9:20733134
wdt:P698
20733134
p:P1433
wds:Q27851579-ACF24FE4-4CA3-4C28-9EB2-F7DC4366A6E6
wdt:P1433
wd:Q400292
p:P433
wds:Q27851579-725F5FF9-501D-46E7-984F-6F1CBBA96303
p:P478
wds:Q27851579-46D02C41-9B76-44D2-AC32-022D8F25D2AF
wdt:P433
28
wdt:P478
28
p:P356
wds:Q27851579-B8AD0601-2C4A-4A4A-98B6-C1B98521AFA9
wdtn:P356
n12:JCO.2010.28.9678
wdt:P356
10.1200/JCO.2010.28.9678
skos:altLabel
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
p:P932
wds:Q27851579-091E3566-C2F7-40BE-8CC1-3B97DC5C9FA7
wdt:P932
4135183